Clinical trial No longer in our active list Phase 3 Interventional Ages 18 and up Men only

Comparing BMS-986365 with standard therapies for advanced prostate cancer

Official title: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

Run by Celgene · NCT06764485 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new drug called BMS-986365 to see if it works better than standard treatments for men with advanced prostate cancer that has spread and is resistant to hormone therapy.

More Metastatic Castration-resistant Prostate Cancer trials Research outlook What's coming for Metastatic prostate cancer: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment960 (estimated)
SponsorCelgene
Industry-sponsored
Drugs / interventionsPrednisone
Locations282 sites (Birmingham, Alabama and 281 other locations)
Trial IDNCT06764485 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include men with confirmed metastatic castration-resistant prostate cancer who have previously received androgen receptor pathway inhibitors.

Probably not a fit

Patients with significant cardiac disease, brain or liver metastases, or those with severe symptoms from prostate cancer may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of BMS-986365 compared to the investigator's choice of therapy in patients with metastatic castration-resistant prostate cancer. Participants will be randomly assigned to receive either BMS-986365 at one of two dose levels or standard treatments such as Docetaxel with Prednisone, Abiraterone with Prednisone, or Enzalutamide. The primary endpoint is to assess radiographic progression-free survival (rPFS) between the treatment groups. The study is divided into two parts, with randomization occurring at different stages to ensure robust data collection.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for patients with advanced prostate cancer.

How similar studies have gone: Other studies have shown promising results with similar approaches in targeting advanced prostate cancer, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

* Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features.
* Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI).
* Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be \< 4.
* Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).

Exclusion Criteria

* Participants must not have impaired cardiac function or clinically significant cardiac disease.
* Participants must not have any brain metastasis.
* Participants must not have any liver metastasis.
* Participants with superscan on technetium-99m (Tc-99m) radionuclide bone scans.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's running

  • Central Alabama Research
    Birmingham, Alabama, United States
    Recruiting
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona, United States
    Recruiting
  • Moores Cancer Center
    La Jolla, California, United States
    Recruiting
  • Cancer and Blood Specialty Clinic
    Los Alamitos, California, United States
    Recruiting
  • California Pacific Medical Center
    San Francisco, California, United States
    Recruiting
  • San Francisco VA Health Care System
    San Francisco, California, United States
    Recruiting
Show 44 more locations
  • Rocky Mountain Regional VA Medical Center
    Aurora, Colorado, United States
    Recruiting
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado, United States
    Recruiting
  • Colorado Clinical Research
    Lakewood, Colorado, United States
    Recruiting
  • Sibley Memorial Hospital
    Washington D.C., District of Columbia, United States
    Recruiting
  • Lakeland Regional Cancer Center
    Lakeland, Florida, United States
    Recruiting
  • Northwestern Memorial Hospital
    Chicago, Illinois, United States
    Recruiting
  • The University of Kansas Cancer Center - Westwood
    Westwood, Kansas, United States
    Recruiting
  • Wichita Urology Group
    Wichita, Kansas, United States
    Recruiting
  • Chesapeake Urology
    Baltimore, Maryland, United States
    Recruiting
  • Johns Hopkins Hospital
    Baltimore, Maryland, United States
    Recruiting
  • James M Stockman Cancer Institute
    Frederick, Maryland, United States
    Recruiting
  • Thomas Jefferson University, Kennedy Health Alliance
    Sewell, New Jersey, United States
    Recruiting
  • University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico, United States
    Recruiting
  • New Mexico Oncology Hematology Consultants Ltd.
    Albuquerque, New Mexico, United States
    Recruiting
  • Roswell Park Cancer Institute
    Buffalo, New York, United States
    Recruiting
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island
    Mineola, New York, United States
    Recruiting
  • Laura and Isaac Perlmutter Cancer Center
    New York, New York, United States
    Recruiting
  • Icahn School of Medicine at Mount Sinai
    New York, New York, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York, United States
    Recruiting
  • Associated Medical Professionals - Urology
    Syracuse, New York, United States
    Recruiting
  • Providence Portland Medical Center
    Portland, Oregon, United States
    Recruiting
  • Providence St. Vincent Medical Center
    Portland, Oregon, United States
    Recruiting
  • Philadelphia Veterans Affairs Medical Center
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Thomas Jefferson University - Clinical Research Institute
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Asplundh Cancer Pavilion
    Willow Grove, Pennsylvania, United States
    Recruiting
  • Hollings Cancer Center
    Charleston, South Carolina, United States
    Recruiting
  • Carolina Urologic Research Center, LLC
    Myrtle Beach, South Carolina, United States
    Recruiting
  • Tennessee Oncology
    Nashville, Tennessee, United States
    Recruiting
  • Texas Oncology - Central/South Texas
    Austin, Texas, United States
    Recruiting
  • Urology Austin, PLLC
    Austin, Texas, United States
    Recruiting
  • University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
    Recruiting
  • Intermountain Medical Center
    Murray, Utah, United States
    Recruiting
  • University of Virginia Cancer Center
    Charlottesville, Virginia, United States
    Recruiting
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin, United States
    Recruiting
  • Hospital Británico de Buenos Aires
    Caba, Buenos Aires, Argentina
    Recruiting
  • Instituto Alexander Fleming
    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Recruiting
  • Hospital Italiano de Buenos Aires
    Abb, Buenos Aires F.D., Argentina
    Recruiting
  • Hospital Italiano de Córdoba
    Córdoba, Córdoba Province, Argentina
    Recruiting
  • Clinica Viedma S. A
    Viedma, R, Argentina
    Recruiting
  • Asociación de Beneficencia Hospital Sirio Libanés
    Buenos Aires, Argentina
    Recruiting
  • Hospital Privado Universitario de Córdoba
    Córdoba, Argentina
    Recruiting
  • GenesisCare - Campbelltown
    Campbelltown, New South Wales, Australia
    Recruiting

+232 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.